---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-287048"
form_type: "8-K"
ticker: "NERV"
cik: "0001598646"
company_name: "Minerva Neurosciences, Inc."
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:27:37.858673+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Minerva Neurosciences appoints Dr. Inderjit Kaul to board; Kaul led Cobenfy schizophrenia program at BMS

## Summary
- Dr. Kaul appointed to Minerva's board (Class II) effective Nov 14, 2025; board size increased to 6.
- Received initial option grant of 9,500 shares vesting quarterly over 3 years; $40,000 annual cash retainer.
- Consulting agreement: $450/hr for 25-30 hrs/month, six-month term; equity top-ups tied to roluperidone milestones.
- Kaul previously SVP Late-Stage Clinical Development at BMS, led Cobenfy development for schizophrenia; currently CMO of Draig Therapeutics.
- Appointment follows recent $200M private placement to fund confirmatory Phase 3 trial of roluperidone.

## SEC filing metadata
- accession: 0001193125-25-287048
- form_type: 8-K
- ticker: NERV
- cik: 0001598646
- company_name: Minerva Neurosciences, Inc.
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1598646/000119312525287048/0001193125-25-287048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1598646/000119312525287048/d48648d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-287048
- JSON: https://secwatch.observer/filing/0001193125-25-287048.json
- Plain text: https://secwatch.observer/filing/0001193125-25-287048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.